Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clearside Biomedical (CLSD)
NASDAQ:CLSD
RESEARCH TOOLSreports
Holding CLSD?
Track your performance easily
CLSD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.92 - $2.12
Previous Close$1.08
Volume275.39K
Average Volume (3M)757.74K
Market Cap
$81.91M
Enterprise Value$59.10M
Total Cash (Recent Filing)$23.59M
Total Debt (Recent Filing)$785.00K
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Mar 18, 2025EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding75,843,504
10 Day Avg. Volume287,419
30 Day Avg. Volume757,741
Standard Deviation0.27
R-Squared0.21
Alpha-0.00172
Financial Highlights & Ratios
Price to Book (P/B)-2.28
Price to Sales (P/S)10.14
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.67
Enterprise Value/Gross Profit7.51
Enterprise Value/Ebitda-2.19
Forecast
1Y Price Target
$5.40Price Target Upside400.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Clearside Biomedical News
PremiumCompany Announcements
Clearside Biomedical Reports Positive Q3 2024 Results
Bulls Say, Bears Say
Bulls Say
Market ValuationConsidering current levels, CLSD appears highly undervalued compared to peers, indicating potential for significant value appreciation.
Product Efficacy And DifferentiationCLS-AX efficacy appears superior to current wet AMD standard of care, positioning it as a potentially more effective treatment option.
Safety ProfileThe lack of intraocular inflammation could differentiate CLS-AX on safety, offering a safer alternative for wet AMD therapies.
Bears Say
Clinical TrialsAny delays or unfavorable outcome from the ongoing or planned clinical trials of Clearside’s pipeline candidates could affect the stock.
Financial PerformanceThe company will need to address its financial overhang for shares to reflect the potential of CLS-AX in wet AMD.
Investor ConcernsShares have been under pressure due to concerns related to four cases of mild intraocular inflammation.
---
Ownership Overview
16.43% Insiders
4.88% Mutual Funds
5.06% Other Institutional Investors
69.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLSD FAQ
What was Clearside Biomedical’s price range in the past 12 months?
Clearside Biomedical lowest stock price was $0.92 and its highest was $2.12 in the past 12 months.
What is Clearside Biomedical’s market cap?
Currently, no data Available
When is Clearside Biomedical’s upcoming earnings report date?
Clearside Biomedical’s upcoming earnings report date is Mar 18, 2025 which is in 112 days.
How were Clearside Biomedical’s earnings last quarter?
Clearside Biomedical released its earnings results on Nov 12, 2024. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.124 by $0.024.
Is Clearside Biomedical overvalued?
According to Wall Street analysts Clearside Biomedical’s price is currently Undervalued.
Does Clearside Biomedical pay dividends?
Clearside Biomedical does not currently pay dividends.
What is Clearside Biomedical’s EPS estimate?
Clearside Biomedical’s EPS estimate is -$0.1.
How many shares outstanding does Clearside Biomedical have?
Clearside Biomedical has 75,843,506 shares outstanding.
What happened to Clearside Biomedical’s price movement after its last earnings report?
Clearside Biomedical reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.124. Following the earnings report the stock price went down -2.703%.
Which hedge fund is a major shareholder of Clearside Biomedical?
Among the largest hedge funds holding Clearside Biomedical’s share is Caxton Associates LP. It holds Clearside Biomedical’s shares valued at N/A.
---
Clearside Biomedical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.40 (400.00% Upside)
$5.40 (400.00% Upside)
Insider Transactions
Bought Shares
Worth $36.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.28%
Trailing 12-Months
Company Description
Clearside Biomedical
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
---
CLSD Earnings Call
Q3 2024
0:00 / 0:00
---
CLSD Stock 12 Month Forecast
Average Price Target
$5.40
▲(400.00% Upside)
Technical Analysis
Best Analysts Covering CLSD
1 Year
1 Year Success Rate
9/15 ratings generated profit
1 Year Average Return
+1.67%
reiterated a buy rating 3 months ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +1.67% per trade.
---